Cargando…

Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma

BACKGROUND: Metastatic melanoma is an incurable disease with an average survival of less than one year. Talabostat is a novel dipeptidyl peptidase inhibitor with immunostimulatory properties. METHODS: This phase II, open label, single arm study was conducted to evaluate the safety and efficacy of 75...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eager, Robert M, Cunningham, C Casey, Senzer, Neil N, Stephenson, Joe, Anthony, Stephen P, O'Day, Steven J, Frenette, Gary, Pavlick, Anna C, Jones, Barry, Uprichard, Margaret, Nemunaitis, John
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731782/ https://www.ncbi.nlm.nih.gov/pubmed/19643020 http://dx.doi.org/10.1186/1471-2407-9-263

Ejemplares similares

Preclinical Assessment of wt GNE Gene Plasmid for Management of Hereditary Inclusion Body Myopathy 2 (HIBM2)
por: Jay, Chris, et al.
Publicado: (2008)

Emerging technologies for the genomic analysis of cancer
por: Nemunaitis, John, et al.
Publicado: (2009)

Letter to the editor: Does Dicer Expression Affect shRNA processing?
por: Senzer, Neil, et al.
Publicado: (2009)

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: let the virus be its own demise
por: Nemunaitis, John, et al.
Publicado: (2020)

Procoagulant inhibitory properties of paclitaxel poliglumex
por: Nemunaitis, John, et al.
Publicado: (2010)

A randomised, phase II study of intetumumab, an anti-α(v)-integrin mAb, alone and with dacarbazine in stage IV melanoma
por: O'Day, S, et al.
Publicado: (2011)

Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced Disease
por: Simmons, Olivia, et al.
Publicado: (2012)

Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients
por: Atzpodien, J, et al.
Publicado: (2007)

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study
por: Kaufman, Howard L., et al.
Publicado: (2016)

Management Issues in Conjunctival Tumours: Conjunctival Melanoma and Primary Acquired Melanosis
por: Cohen, Victoria M. L., et al.
Publicado: (2019)

Safety and in vivo Expression of a GNE-Transgene: A Novel Treatment Approach for Hereditary Inclusion Body Myopathy-2
por: Phadke, Anagha P., et al.
Publicado: (2009)

Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series
por: Finger, Paul T., et al.
Publicado: (2019)

Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy
por: Alqahtani, Ali, et al.
Publicado: (2019)

KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex
por: Rao, Donald D., et al.
Publicado: (2018)

Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma
por: Ghisoli, Maurizio, et al.
Publicado: (2015)

Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma
por: Rao, Donald D., et al.
Publicado: (2016)

1716P Vigil plasmid (VP), a dual bi-shRNA-furin/GMCSF construct from cancer to SARS-CoV-2
por: Jay, C., et al.
Publicado: (2020)

Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine
por: Propper, D J, et al.
Publicado: (2000)

Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma
por: Andtbacka, Robert H. I., et al.
Publicado: (2016)

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
por: Dummer, Reinhard, et al.
Publicado: (2015)

Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial
por: Boudewijns, Steve, et al.
Publicado: (2020)

Anvirzel™ in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines
por: Apostolou, Panagiotis, et al.
Publicado: (2013)

Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
por: Pectasides, D., et al.
Publicado: (1989)

Notch1 Activation Up-Regulates Pancreatic and Duodenal Homeobox-1
por: Liu, Shi-He, et al.
Publicado: (2013)

Lei Wang: Expanding the language of life
por: O'Day, Kira
Publicado: (2008)

Andrea Cooper: Using pathogens to probe the immune response
por: O'Day, Kira
Publicado: (2008)

Gut Reaction: Pyrosequencing Provides the Poop on Distal Gut Bacteria
por: O'Day, Kira
Publicado: (2008)

Completing the Candida Loop
por: O'Day, Kira
Publicado: (2007)

Cisplatin Resistance and Redox-Metabolic Vulnerability: A Second Alteration
por: Wangpaichitr, Medhi, et al.
Publicado: (2021)

Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial
por: Ellingsen, Espen B., et al.
Publicado: (2023)

Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases
por: In, Gino K., et al.
Publicado: (2020)

Co-delivery of Cisplatin(IV) and Capecitabine as an Effective and Non-toxic Cancer Treatment
por: Xiao, Xiao, et al.
Publicado: (2019)

Cisplatin fails to induce puma mediated apoptosis in mucosal melanomas
por: Fritsche, Marie Kristin, et al.
Publicado: (2015)

Shedding Light on Animal Cryptochromes
por: O'Day, Kira E
Publicado: (2008)

An Enzymatic Palimpsest
por: O'Day, Kira E
Publicado: (2008)

Secretory Protein mRNA Finds Another Way Out
por: O'Day, Kira E
Publicado: (2007)

Omnidirectional Electric Fish
por: O'Day, Kira E
Publicado: (2007)

Conspicuous Chameleons
por: O'Day, Kira E
Publicado: (2008)

Proteins of the Nucleolus of Dictyostelium discoideum: Nucleolar Compartmentalization, Targeting Sequences, Protein Translocations and Binding Partners
por: O’Day, Danton H.
Publicado: (2019)

Calmodulin Binding Proteins and Alzheimer’s Disease: Biomarkers, Regulatory Enzymes and Receptors That Are Regulated by Calmodulin
por: O’Day, Danton H.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4mdti7fet30es33dja298aj92l